| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
- |
| Employees |
207 |
| Revenues (TTM) (Millions $) |
337 |
| Net Income (TTM) (Millions $) |
-42 |
| Cash Flow (TTM) (Millions $) |
-235 |
| Capital Exp. (TTM) (Millions $) |
1 |
Business Description
Akcea Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious and rare diseases. Established in 2015, it operates as a subsidiary of Ionis Pharmaceuticals, a pioneer in RNA-targeted therapeutic technologies.
Akcea has a robust pipeline of potential drugs that target specific rare diseases, including those related to lipid metabolism, cardiovascular diseases, neurodegenerative disorders, and rare genetic disorders. In 2019, the company received its first drug approval, TEGSEDI, for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis, a rare and fatal genetic disease.
The company's main product, WAYLIVRA (Volanesorsen), is a treatment for people with Familial Chylomicronemia Syndrome (FCS), a rare genetic condition that affects the body's ability to break down fats. WAYLIVRA has received approval from the European Commission, and the company is awaiting approval from the US FDA.
Akcea's drug development platform is built upon Ionis Pharmacuticals' proprietary antisense technology, which targets RNA of specific genes to reduce the production of harmful proteins that cause diseases. This technology has been validated in the market through the success of Ionis' drugs, including Spinraza, a treatment for spinal muscular atrophy.
The company has partnerships with pharmaceutical and biotechnology companies to develop and commercialize its products, including Novartis for TEGSEDI and Bayer for WAYLIVRA.
Overall, Akcea Therapeutics is committed to bringing new treatment options to patients with rare and underserved diseases, leveraging the cutting-edge antisense technology platform of its parent company, Ionis Pharmaceuticals.
Company Address: 22 Boston Wharf Road Boston 2210 MA
Company Phone Number: 207-0202 Stock Exchange / Ticker: NASDAQ AKCA
|
%